angiotensin receptor blockers (ARBs) - for COVID-19 method

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA
clinical worsening 0.77 [0.36, 1.64]< 10%1 study (- / 1)75.1 %criticalnot evaluable very lowcrucial-
deaths 1.15 [0.95, 1.39]< 10%1 study (- / 1)7.1 %seriousnot evaluable lowcrucial-
deaths (time to event analysis only) 1.15 [0.95, 1.39]< 10%1 study (- / 1)7.1 %seriousnot evaluable lowcrucial-
hospitalization 0.88 [0.61, 1.26]< 10%1 study (- / 1)76.2 %seriousnot evaluable lowimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 2 pathologies: 87,95,94,90,91,97 95, 97